Responses

I would like to submit a request for information under the Freedom of Information Act 2000 (FOIA) regarding cases of food poisoning due to incorrect identification or inappropriate preparation of wild food.

Please provide the relevant information for the period between 1 April 2020 and the most recent date for which data is available. Please could you provide the following:

A yearly breakdown of the number of cases of food poisoning due to incorrect identification or inappropriate preparation of wild food.
The type of wild food that caused the food poisoning (for example: fungi, plant, berries, etc…). Please include the specific species if known.
The symptoms experienced by the patient and the recovery time (for example: overnight stay or discharged within a couple hours)
The location where this food was picked. We would define ‘wild or foraged’ foods to be either: Wild, naturally growing food which was picked and consumed by an individual Wild, naturally growing food which was consumed by an individual, but was served in a restaurant environment, having been picked in the wild within the UK.

If you need to carry out a key terms search to locate these records, please include the terms “foraged”, “foraging”, “wild food”, “forager”, “wild ingredients”. If you would document these cases in another way, please include these results as per the spirit of my request.

If you feel that my request is unclear or too broad, I would be grateful if you could provide me with some guidance as to how I could refine it.

I am writing to request information under the Freedom of Information Act 2000 regarding your compliance with the Learning from Deaths Guidance issued by NHS England (2017) which ensures your trust complies with the National Health Service (Quality Accounts) (Amendment) Regulations 2017.

This requires every NHS Trust to annually report (with a quarterly breakdown) the number of patients who died during the reporting period, how many case record reviews or investigations took place, and estimate how many deaths were determined to be likely due to problems in the care provided. It also requires the reporting of a summary of lessons learnt, what actions have been taken as a result, and what the impact of these actions has been.

Included in the Quality Accounts should also be the number of case record reviews and investigations relating to deaths in the previous reporting period that were only concluded in the most recent period and an estimation of how many of those deaths were due to problems in the care provided.

Please provide answers to the following questions for the most recent reporting period (2023/24):

1. Policy and Governance
a) Does your trust currently comply with the requirements of the Leaming from Deaths Guidance?
b) If not do you have plans to comply with it and if so by when?
 
2. Reporting
a) How many deaths were reported within your trust during the reporting period (2023/24)?
b) How many of these deaths were reviewed, and how many were judged more likely than not to have been avoidable?
c) Have you published quarterly reports on learning from deaths on your website, as required by the guidance? Please provide links to the most recent reports.
d) Is information on learning from deaths included in your latest Quality Account?

3. Family Involvement
a) Are families and carers involved in the review process where appropriate?
b) Please provide the number of deaths that were reviewed in this period (2023/24) where families and carers were involved and engaged in the review.

4. Actions and Learning
a) Please provide a summary of all actions taken as a result of the learning from deaths process in the last reporting period.

Please can I request the below information on the utilisation of Insourcing for the following period 01/01/2025-31/03/2025

• Total spend during the period for Insourcing for the below specialties:

• Neurology
• Neurophysiology
• Dermatology
• Gastroenterology
• Endoscopy
• Cardiology
• Respiratory
• Orthodontics / Dental
• OMFS
• ENT
• Rheumatology
• Gynaecology

– Please break the spend down by insourcing company

• Please confirm if there was a budget for insourcing for the specialties outlined during the same period

• What was the service type relating to the specialties outlined, for example, outpatient, diagnostic or theatres.

• Was it a fully managed service or Team provision

• Please can you confirm the Frameworks utilised for each specialty

• Please confirm any direct awards or mini competitions which are being utilised for each specialty

• Total procedures completed by insourcing companies for the specialties outlined during the same period

Under the Freedom of Information Act (2000), please provide the following information:

In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that are greater than 0.3ppm but less than or equal to 0.4ppm in the Trust’s Histopathology Department? In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that are greater than 0.4ppm but less than or equal to 0.5ppm in the Trust’s Histopathology Department? In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that are greater than 0.5ppm but less than or equal to 0.6ppm in the Trust’s Histopathology Department? In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that are greater than 0.6ppm but less than or equal to 0.7ppm in the Trust’s Histopathology Department? In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that are greater than 0.7ppm but less than or equal to 0.8ppm in the Trust’s Histopathology Department? In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that are greater than 0.8ppm but less than or equal to 0.9ppm in the Trust’s Histopathology Department? In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that are greater than 0.9ppm but less than or equal to 1ppm in the Trust’s Histopathology Department? In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that are greater than 1ppm but less than or equal to 1.5ppm in the Trust’s Histopathology Department? In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that are greater than 1.5ppm but less than or equal to 2ppm in the Trust’s Histopathology Department? In the past 12 months, on how many separate occasions have formaldehyde levels been recorded that exceed 2ppm in the Trust’s Histopathology Department?

May I please ask for the following information under the FOI act.

1. Does your NHS Trust/Board have an executive board where health research strategy for the hospital/s is set? e.g a Research and Innovation Board or other relevant high-level board.
2. If yes, is there a PPIE (patient public involvement engagement) representative on this board with the specific remit to provide insights into research agenda setting from the perspective of a patient with lived experience of health issues or as a member of the public/community? [I am not referring to the presence of a lay chair].
3. Is there a PPIE advisory structure (e.g. board, committee, panel) which provides PPIE insights to inform the work of the executive board? (not within individual study groups- I refer to high level feedback into your research strategy meetings).
4. If yes to question 2, 3, 4 or 5, please provide the most recent minutes/agenda with a list of members with designated roles/remits (not names).
5. Are PPIE representatives remunerated?
6. Do you require PPIE representatives to do any training? If yes, please specify e.g NIHR training or in house-training.
7. I realise that some of this information may already be available. However, I was unable to locate it. So, if it is, please provide me with a link to the data.

This is a Freedom of Information request for information relating to the letter this summer from Dame Emily Lawson and Vin Diwaker, to all trust executives and COOs, asking them to confirm “that [they] plan to adopt the NHS FDP in the next two years”.

I would like to see all emails, documents, attachments, and any other forms of response relating to this request between Gloucestershire Health and Care NHS Foundation Trust and the two senior NHS officials.

It is public information that you have been asked to inform the NHS when you “envisage adopting already available nationally commissioned local Products”.

I would like to know when specifically you plan to start adopting the FDP and who you are naming as lead (as is requested in the letter)?

I would also like to know what your plans are for how you will maximise the benefits of the Federated Data Platform to deliver better joined-up care for their patients within the next two years (again, asked of you in the above mentioned letter)?

We would like to request the following information from Gloucestershire Health & Care NHS Foundation Trust

1) We have the following formularies listed as used by the organisation:
Gloucestershire Joint Formulary
Please confirm if this is correct and if not, please provide any relevant online links or copies of formularies.

2) We understand the following committees maintain the formularies in question 1:
One Gloucestershire Medicines Optimisation Board (OGMOB)
Please confirm if this is correct. If not correct, please list the relevant committees with the corresponding formulary.

3) Does the organisation have representation on the committees listed in question 2?

4) Are any of the above formularies listed in question 1 dominant when making prescribing decisions or does this depend on therapy area? Please say which is the dominant formulary of the organisation.

5) If you use a PDF formulary, have you considered moving it to an online platform like Netformulary, and if yes, when are you planning to do so?

6) Request for Re-use
If your organisation does hold this information and is able to share it, then I would like to submit the following request for re-using the information:

We (IQVIA) request permission to re-use the information provided as part of independent analyses commissioned by our clients. The contents of the reports will not be made available publicly but may be used by other IQVIA Group entities and service suppliers. The information in the reports will be presented in a factual manner with all publication details staying true to the publisher.